Condition category
Infections and Infestations
Date applied
23/09/2009
Date assigned
24/09/2009
Last edited
09/02/2011
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

http://www.swineflutrial.org/

Contact information

Type

Scientific

Primary contact

Prof Andrew Pollard

ORCID ID

Contact details

Oxford Vaccine Group
University of Oxford Department of Paediatrics
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Churchill Hospital
Old Road
Headington
Oxford
OX3 7LJ
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

NCT00980850

Protocol/serial number

HTA 09/94/01; 2009/08 H1N1

Study information

Scientific title

Open label, randomised, parallel-group, multi-centre study to evaluate the safety, tolerability and immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age

Acronym

Study hypothesis

In the first half of this year a novel Influenza A H1N1 virus has resulted in an influenza pandemic. The United Kingdom has seen a particularly high incidence of disease. The highest rates of disease are being seen in young children. In anticipation of an influenza pandemic two vaccine manufacturers, Baxter and GlaxoSmithKline, have gained marketing authorisation approval from the European Medicines Agency (EMEA) for a pandemic strain vaccine under the "mockup" dossier route based on limited clinical trial data for a candidate H5N1 vaccine. This "mockup" dossier route for pandemic influenza vaccines allows the submission of a core pandemic dossier during the interpandemic period, which results in the approval of a mockup pandemic vaccine. This is followed by a fast track approval of the pandemic vaccine based on the submission of the pandemic variation when the situation arises. The Baxter and GlaxoSmithKline vaccines have now been modified to cover the novel influenza A H1N1 strain.

Given the high rates of swine flu disease in children, this age group is likely to particularly benefit from immunisation against this virus, however there are few data on the use of these vaccines in a paediatric population. The proposed study therefore aims to assess the immunogenicity, safety, and tolerability of these two H1N1 vaccines when administered as two doses three weeks apart to children aged 6 months to 12 years of age.

Ethics approval

Oxford Research Ethics Committee A, approved on 18/09/2009 (ref: 09/18/2009)

Study design

Phase II open-label randomised parallel-group multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Prevention

Patient information sheet

Patient information can be found at: http://www.swineflutrial.org/swineflu_screen.html#information

Condition

Influenza

Intervention

Baxter Novel Influenza A H1N1 Whole Virus Vaccine. Other Name: Celvapan®
Two 0.5 ml doses of vaccine given within 3 weeks interval given intramuscularly

GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine. Other Name: Pandemrix®
Two 0.25 ml doses of vaccine given within 3 weeks interval given intramuscularly.

Follow up period: 3 weeks after second vaccine dose

Intervention type

Drug

Phase

Phase II

Drug names

Baxter Influenza A H1N1 Whole Virus Vaccine (Celvapan®), GlaxoSmithKline Influenza A H1N1 Split Virion Vaccine (Pandemrix®)

Primary outcome measures

1. Percentage of subjects with a 4 fold rise in microneutralisation (MN) titre between the pre-vaccination sample and sample taken 3 weeks after the second dose
2. Percentage of participants experiencing each of fever (>=38°C per axilla), local tenderness, local swelling or local erythema within the 7 days following each immunisation with the study vaccines

Secondary outcome measures

1. Percentage of subjects with an HAI titre >=1 in 32, assessed 3 weeks after completion of a two dose course of vaccination
2. Percentage of subjects with a 4 fold rise in HAI titre between the pre-vaccination sample and sample taken 3 weeks after the second dose
3. The geometric mean fold rises in HAI titres from baseline to after 3 weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine
4. The geometric mean fold rises in MN titres from baseline to 3 weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine
5. The geometric mean HAI and MN titres 3 weeks after 2 doses of the Baxter H1N1 vaccine and the GSK H1N1 vaccine
6. Percentage of participants experiencing each of: reduced feeding, reduced activity, irritability, persistent crying, vomiting or diarrhoea, receiving medication for pain or temperature (6 month to 5 year olds)
7. Percentage of participants experiencing each of: malaise, headache, nausea/ vomiting, diarrhoea, reduced appetite, muscle pain or joint pain, receiving analgesic/ antipyretic medication (5 to 12 year olds)
8. The effect of genetic polymorphisms on the immunogenicity and reactogenicity of the H1N1 vaccines

Overall trial start date

26/09/2009

Overall trial end date

27/09/2010

Reason abandoned

Eligibility

Participant inclusion criteria

1. Baby or child (both males and females) aged between 6 months to 12 years of age (i.e., to day before 13th birthday)
2. For whom a parent/legal guardian has given written informed consent after the nature of the study has been explained
3. Available for all the visits scheduled in the study
4. Willingness to complete all study procedures

Participant type

Patient

Age group

Child

Gender

Both

Target number of participants

1,000

Participant exclusion criteria

1. History of any vaccine against novel influenza A strain H1N1 (based on verbal confirmation from parent/guardian)
2. Previous laboratory confirmed case of novel influenza A strain H1N1 or treatment with oseltamivir or zanamivir for novel influenza A strain H1N1 (n.b. a child commenced on treatment with oseltamivir or zanamivir for novel influenza A strain H1N1 whose treatment was stopped following negative microbiological tests for H1N1 on nasal swabs would be allowed to enrol in the study)
3. History of severe allergic reaction after previous vaccinations or hypersensitivity to any H1N1 vaccine component
4. Current egg allergy
5. Known or suspected impairment/alteration of the immune system
6. Disorders of coagulation
7. Immunosuppressive therapy, use of systemic corticosteroids for more than 1 week within the 3 months prior to enrolment
8. Receipt of blood, blood products and/or plasma derivatives or any immunoglobulin preparation within 3 months prior to enrolment
9. Intent to immunise with any other vaccine(s) against novel influenza A strain H1N1 throughout the study period
10. Participation in another clinical trial of an investigational medical product
11. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives. Children with chronic, stable medical illnesses that do not result in immunosuppression (e.g., cerebral palsy, epilepsy, cystic fibrosis, congenital heart disease) will be allowed to participate in the study, unless these conditions will in some way interfere with the completion of study procedures. Children with conditions that may alter the immune response to vaccines (e.g., Trisomy 21) or will affect the ability to accurately describe adverse events (e.g., children over 5 years of age but with severe learning difficulties) will be excluded

Recruitment start date

26/09/2009

Recruitment end date

27/09/2010

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Oxford Vaccine Group
Oxford
OX3 7LJ
United Kingdom

Sponsor information

Organisation

University of Oxford (UK)

Sponsor details

c/o Heather House
Clinical Trials and Research Governance Office
Manor House
Oxford
OX3 9DU
United Kingdom

Sponsor type

University/education

Website

http://www.ox.ac.uk/

Funders

Funder type

Government

Funder name

NIHR Health Technology Assessment Programme - HTA (UK) - HTA Clinical Evaluation and Trials

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20508026
2. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/20923610

Publication citations

  1. Results

    Waddington C, Andrews N, Hoschler K, Walker W, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston P, Allen R, Okike I, Ladhani S, Sheasby E, Waight P, Collinson A, Heath P, Finn A, Faust S, Snape M, Miller E, Pollard A, Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age., Health Technol Assess, 2010, 14, 46, 1-130, doi: 10.3310/hta14460-01.

  2. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ, Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study., BMJ, 2010, 340, c2649.

Additional files

Editorial Notes